Schedule a Meeting
T2Bacteria® Panel
The first and only in-vitro diagnostic test to receive approval for a New Technology Add-On Payment (NTAP) by CMS
LEARN MORE

"The T2Bacteria Test Panel represents a substantial clinical improvement over existing technologies because it reduces the proportion of patients on inappropriate therapy, thus reducing the rate of subsequent diagnostic or therapeutic intervention as well as length of stay and mortality rates caused by sepsis causing bacterial infections."

– US CMS FY 2020 inpatient prospective payments system final rule
T2Bacteria® Panel
The first and only in-vitro diagnostic test to receive approval for a New Technology Add-On Payment (NTAP) by CMS
LEARN MORE

"The T2Bacteria Test Panel represents a substantial clinical improvement over existing technologies because it reduces the proportion of patients on inappropriate therapy, thus reducing the rate of subsequent diagnostic or therapeutic intervention as well as length of stay and mortality rates caused by sepsis causing bacterial infections."

– US CMS FY 2020 inpatient prospective payments system final rule

T2 could save lives – bottomline.

  • Get patients on the right therapy faster
  • Improve morbidity and mortality outcomes
  • Reduce costs
  • Improve antimicrobial stewardship
Learn More

Now, hospitals can detect and identify sepsis-causing pathogens faster and more accurately.

Hospitals trust in T2 technology.

Gregorio Marañón Hospital in Madrid, Spain
Two 2018 studies from Gregorio Marañón Hospital in Madrid, Spain.
Learn More
Rigshospitalet, Denmark
"T2Candida was superior to blood culture and mannan antigen and may improve diagnosis."
Learn More
Gemelli Hospital, Italy
66.7% of the clinically infected patients missed by blood culture were correctly identified by T2Bacteria
Learn More
La Paz Hospital University, Spain
T2Candia Panel contributed to the healthy discharge of a 1-year-old transplant patient.
Learn More

Patient Case Studies

Real stories about how T2 Biosystems™ could have potentially changed clinical practice and patient outcomes.

Secondary Candidemia in Critically Ill COVID-19 Patient

T2Candida enabled the detection of candidemia 29 hours before a positive blood culture was returned. Early detection allowed for the rapid initiation of antifungal therapy in a critically ill COVID-19 patient.
Read Case Study

Case Study 1

53-year-old immunocompromised, female with recent surgery to drain an intra-abdominal abscess
Read Case Study

Case Study 2

25-year-old female with cerebral palsy diagnosed with duodenal pneumatosis
Read Case Study

Case Study 3

73-year-old female with lymphoma on chemotherapy and diagnosed with pneumonia and septic shock
Read Case Study
Previous
Next

Numbers don't lie.

Mortality increases

8%
each hour of delayed treatment

Sepsis kills

~6 million
people worldwide annually.

Sepsis impacts

30 million
people worldwide each year.
Integrate T2Direct Diagnostics into your hospital today!
Learn More

Stewardship Case Studies

Secondary Candidemia in Critically Ill COVID-19 Patient

T2 BIOSYSTEMS OVERVIEW

T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.

The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.

T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.

© 2022 T2 Biosystems, Inc.

JOIN IN ON TWITTER

SITEMAP

FOLLOW US ON SOCIAL

Linkedin-in Twitter

Please tell us where you are visiting from: United States | Outside the United States